Methyldopa Accord-Uk (Anhydrous Methyldopa)

Methyldopa is metabolized to alpha‑methylnorepinephrine, which activates central alpha‑2 adrenergic receptors. This activation reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and ultimately lowering arterial blood pressure.

The appropriate dose of methyldopa is individualized by the prescribing clinician based on the patient’s blood pressure, response, and tolerability. Dosage adjustments are made according to clinical guidelines and patient monitoring.

Methyldopa is classified as pregnancy category B, indicating it is generally considered safe for use during pregnancy when prescribed by a healthcare professional. Limited data are available for breastfeeding, so use should be discussed with a physician.

To request Methyldopa Accord-Uk, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Methyldopa is a centrally acting alpha‑2 agonist, differing from diuretics, ACE inhibitors, or calcium‑channel blockers that act peripherally. It is especially valued in pregnancy because of its safety profile, whereas many other antihypertensives are contraindicated or used with caution during gestation.

Methyldopa Accord-Uk should be stored at temperatures below 25 °C in its original packaging. Protect the product from moisture and direct sunlight to maintain its stability and potency throughout its shelf life.

Methyldopa Accord-Uk is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The exact administration schedule is determined by the prescribing clinician based on therapeutic response.

Serious risks include severe hypotension, liver dysfunction, hemolytic anemia, agranulocytosis, and rare immune‑mediated reactions such as Stevens‑Johnson syndrome or lupus‑like syndrome. Patients should be monitored regularly for these potential complications.

Methyldopa is contraindicated in patients with known hypersensitivity to the drug, severe liver disease, or those taking monoamine oxidase inhibitors. Caution is also advised for individuals with renal impairment or a history of autoimmune disorders.